197 related articles for article (PubMed ID: 15053780)
1. Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice.
Daneshvar H; Hagan P; Phillips RS
Parasite Immunol; 2003; 25(11-12):589-96. PubMed ID: 15053780
[TBL] [Abstract][Full Text] [Related]
2. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines.
Daneshvar H; Coombs GH; Hagan P; Phillips RS
J Infect Dis; 2003 May; 187(10):1662-8. PubMed ID: 12721947
[TBL] [Abstract][Full Text] [Related]
3. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
Alexander J; Coombs GH; Mottram JC
J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
[TBL] [Abstract][Full Text] [Related]
4. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.
Stamm LM; Räisänen-Sokolowski A; Okano M; Russell ME; David JR; Satoskar AR
J Immunol; 1998 Dec; 161(11):6180-8. PubMed ID: 9834104
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
6. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
7. Gentamicin-attenuated Leishmania infantum: a clinicopathological study in dogs.
Daneshvar H; Molaei MM; Afshar RM; Kamiabi H; Burchmore R; Hagan P; Phillips RS
Vet Immunol Immunopathol; 2009 May; 129(1-2):28-35. PubMed ID: 19147233
[TBL] [Abstract][Full Text] [Related]
8. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
Halliday A; Bates PA; Chance ML; Taylor MJ
Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
[TBL] [Abstract][Full Text] [Related]
10. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model.
Ali SA; Rezvan H; McArdle SE; Khodadadi A; Asteal FA; Rees RC
Parasite Immunol; 2009 Jul; 31(7):373-83. PubMed ID: 19527453
[TBL] [Abstract][Full Text] [Related]
11. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection.
Alexander J; Brombacher F; McGachy HA; McKenzie AN; Walker W; Carter KC
Eur J Immunol; 2002 Oct; 32(10):2923-33. PubMed ID: 12355446
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana.
Dey R; Natarajan G; Bhattacharya P; Cummings H; Dagur PK; Terrazas C; Selvapandiyan A; McCoy JP; Duncan R; Satoskar AR; Nakhasi HL
J Immunol; 2014 Oct; 193(7):3513-27. PubMed ID: 25156362
[TBL] [Abstract][Full Text] [Related]
13. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis.
Daneshvar H; Molaei MM; Kamiabi H; Burchmore R; Hagan P; Stephen Phillips R
Parasite Immunol; 2010; 32(11-12):722-30. PubMed ID: 21039612
[TBL] [Abstract][Full Text] [Related]
14. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
16. Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major.
Daneshvar H; Burchmore R; Hagan P; Phillips RS
Parasitology; 2009 Sep; 136(11):1243-50. PubMed ID: 19646303
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models.
Saravia NG; Escorcia B; Osorio Y; Valderrama L; Brooks D; Arteaga L; Coombs G; Mottram J; Travi BL
Vaccine; 2006 May; 24(19):4247-59. PubMed ID: 16216395
[TBL] [Abstract][Full Text] [Related]
18. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis.
Satoskar A; Brombacher F; Dai WJ; McInnes I; Liew FY; Alexander J; Walker W
J Immunol; 1997 Nov; 159(10):5005-13. PubMed ID: 9366428
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
20. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Dumonteil E
Vaccine; 2005 Nov; 23(46-47):5372-9. PubMed ID: 16054271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
